Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
Intra-Cellular Therapies Analyst Ratings
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $95
JPMorgan Chase & Co's Strategic Acquisition of Shares in Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Path To Profitability
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies analyst Andrew Tsai maintains $Intra-Cellular Therapies(ITCI.US)$ with a buy rating, and maintains the target price at $105.According to TipRanks data, the analyst has a success rate of 56.4
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Fantastic 798% Return Over the Last Five Years
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
S&P 500 Futures Climb In Premarket Trading; Summit Therapeutics, Palantir Technologies Lead
Piper Sandler Ups Intra-Cellular to Overweight, Cites Caplyta Potential
Expert Ratings For Intra-Cellular Therapies
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler
Piper Sandler Upgrades Intra-Cellular Therapies(ITCI.US) to Buy Rating, Raises Target Price to $92
Piper Sandler analyst David Amsellem upgrades $Intra-Cellular Therapies(ITCI.US)$ to a buy rating, and adjusts the target price from $59 to $92.According to TipRanks data, the analyst has a success
Intra-Cellular Therapies(ITCI.US) Officer Sells US$5.09 Million in Common Stock
$Intra-Cellular Therapies(ITCI.US)$ Officer Mates Sharon sold 70,000 shares of common stock on Aug 29, 30, 2024 at an average price of $72.7034 for a total value of $5.09 million.Source:
Intra-Cellular Therapies(ITCI.US) Officer Sells US$7.05 Million in Common Stock
$Intra-Cellular Therapies(ITCI.US)$ Officer Mates Sharon sold 95,925 shares of common stock on Aug 26, 27, 28, 2024 at an average price of $73.5375 for a total value of $7.05 million.Source: